17/04/2023 - Abivax SA: EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis

[X]
Eqs-news: abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis

The text version of this document is not available. You can access the original document here.

Disclaimer

Abivax SA published this content on 17 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 April 2023 16:12:12 UTC.

MoneyController ti propone anche

Condividi